Clinical trials
Phase 2 Frontotemporal Dementia trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
14 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2005 | 1 |
| 2008 | 1 |
| 2014 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2024 | 1 |
| 2025 | 2 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 6 |
| Active, not recruiting | 2 |
| Enrolling by invitation | 2 |
| Recruiting | 2 |
| Unknown status | 2 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Columbia University | 3 |
| Adam Boxer | 2 |
| Alector Inc. | 1 |
| EIP Pharma Inc | 1 |
| FORUM Pharmaceuticals Inc | 1 |
| Johns Hopkins University | 1 |
| London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 1 |
| National Institute of Neurological Disorders and Stroke (NINDS) | 1 |
| Transposon Therapeutics, Inc. | 1 |
| University of Chicago | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Frontotemporal Dementia | 14 |
| Amyotrophic Lateral Sclerosis | 2 |
| Aphasia | 2 |
| Aphasia, Primary Progressive | 2 |
| Dementia | 2 |
| Frontotemporal Lobar Degeneration | 2 |
| Pick Disease of the Brain | 2 |
| Supranuclear Palsy, Progressive | 2 |
| Alzheimer Disease | 1 |
| Brain Diseases | 1 |
Trials
Showing 1 to 14 of 14. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.